In this period, new NSCLC treatments emerged with focusing more on specific mutations or expressions like anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), c-ros oncogene 1 (ROS1) and programmed death-(ligand) 1 (PD-(L)1) expression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.